XTalks

DECEMBER 13, 2023

Current treatments for sickle cell disease include blood transfusions but patients often have episodes of intense pain and an increased risk of stroke. A bone marrow transplant from a donor can offer a potential cure, but it is often difficult to find a matching donor and the procedure carries the risk of rejection by the immune system.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

Regulation 97

Regulation Marketing Sales Branding 97

pharmaphorum

NOVEMBER 24, 2022

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide. and 17.6%, respectively, according to J&J’s pharma unit Janssen.

Trials 52

Trials Sales Drugs Marketing 52

Intouch Solutions

APRIL 11, 2024

Allowing for people with health conditions (and their caregivers) to become more aware of the disorders they face, thus streamlining the patient journey and reducing the risk associated with following incorrect treatments. Pre-Clinical : Deeper comprehension of the impacts and outcomes associated with a particular drug.

Compliance 52

Compliance Marketing Drugs Pharma Companies 52

pharmaphorum

AUGUST 28, 2020

We are ingesting hundreds of thousands of pieces of information daily and we tag that information across locations, disease types, species, and case counts. And symptom tracker apps, many of which feature self-assessment questionnaires, have helped take the discipline from data mining to direct data collection. “We’ve

Medicine 72

Medicine Research 72

Pharmaceutical Technology

JANUARY 27, 2023

The program follows the lead of Pfizer’s warranty programs for Panzyga (immune globulin intravenous) and Xalkori (crizotinib), as pharma continues to explore new types of risk sharing agreements. In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130

XTalks

AUGUST 23, 2021

But these aims must be balanced with the third principle of protecting study participants from unnecessary risks, like those that may result from preventing patients from accessing available therapies to maintain the integrity of the treatment and placebo arms of the trial. Will they drop out to take it? Safety Monitoring Considerations.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Rethinking Clinical Trials

MARCH 21, 2023

Quality of life (QOL) was assessed at 6 months. When you have more than one choice for the symptom domain or you run the risk of duplication how do you choose? We conducted a large single-center “STAR” Study to find out if the gap between patient and clinician reported symptoms makes an impact on clinical outcomes.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

XTalks

SEPTEMBER 27, 2022

Treatment options prior to Skysona were limited to allogeneic hematopoietic stem cell transplant (allo-HSCT), which has a high risk of serious complications including death, particularly in patients without a human leukocyte antigen (HLA)-matched donor. Related: Bluebird’s $2.8M

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52

pharmaphorum

DECEMBER 7, 2021

Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a lower risk of developing Alzheimer’s disease – a link that they say should be examined more closely in clinical trials. Sildenafil is also sold as Revatio to treat pulmonary artery hypertension (PAH).

Drugs 52

Drugs Clinical Trials Clinical Trials Scientist 52

pharmaphorum

SEPTEMBER 30, 2022

Regulatory reviewers must then manually ‘mine’ the documents for information, rather than assessing the underlying data used to create the documents. This situation results in a complex decision-making environment, with high rates of inefficiency, subjectivity, and risk of error. Reasons for the shift.

Compliance 52

Compliance Life Science Marketing Production 52

XTalks

DECEMBER 21, 2022

In 2022, the US Food and Drug Administration (FDA) approved the following four new gene therapies: Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

XTalks

NOVEMBER 27, 2021

The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529, The independent group of experts is assigned the job of periodically monitoring and assessing the evolution of SARS-CoV-2, including looking at mutations that could change the behavior of the virus.

Vaccination 97

Vaccination Vaccine Protein Scientist 97

Drug Discovery World

NOVEMBER 9, 2023

They will present on expression and characterisation of novel GCN-related N-acetyltransferases by Nucleras rapid protein assess system. Vincent Muczynski, PhD, Director, NovalGen, on: ‘Development of autoregulating FVIII-mimetic bispecific antibodies to reduce risk of prothrombotic events in treatment of haemophilia A’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MAY 4, 2021

The study was designed to assess the safety and efficacy of continued treatment with relugolix combination therapy for up to two years. mg) in healthy women ages 18-35 who are at risk for pregnancy. mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. mg and norethindrone acetate 0.5

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

MAY 5, 2021

. Pfizer’s Hospira recalls hospital anesthetics, flags ‘moderate to high severity’ safety risks ( Fierce ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). Remote Regulatory Assessments ( FDAatty ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52